Health Catalyst (HCAT) Expected to Announce Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Health Catalyst to post earnings of ($0.02) per share and revenue of $55.39 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. The firm had revenue of $70.49 million for the quarter, compared to the consensus estimate of $69.09 million. On average, analysts expect Health Catalyst to post ($0.18) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

Health Catalyst Trading Up 14.6%

HCAT opened at $1.80 on Thursday. The company has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.73. The stock has a market capitalization of $135.47 million, a price-to-earnings ratio of -0.49 and a beta of 1.54. The company has a quick ratio of 2.70, a current ratio of 2.70 and a debt-to-equity ratio of 1.51. Health Catalyst has a twelve month low of $0.96 and a twelve month high of $3.62.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HCAT shares. Wells Fargo & Company dropped their price target on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research note on Thursday, August 13th. Citigroup decreased their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Health Catalyst in a research note on Monday. Finally, Canaccord Genuity Group downgraded Health Catalyst from a “buy” rating to a “hold” rating and dropped their price objective for the company from $3.00 to $1.80 in a research note on Thursday, August 20th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $2.01.

Insider Activity at Health Catalyst

In other Health Catalyst news, CEO Simeon Kohl acquired 59,000 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average cost of $1.79 per share, for a total transaction of $105,610.00. Following the acquisition, the chief executive officer owned 2,856,385 shares in the company, valued at $5,112,929.15. The trade was a 2.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 19.40% of the stock is owned by insiders.

Health Catalyst Company Profile

Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.

The company’s offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.